IL6 and breast cancer: However, in addition to the effect of IL-6 antagonists, anti-IL-6 receptors, and knockdown of OSM on IL-6 expression, a reduced level of IL-6 was also observed in blood samples of women with breast cancer bone metastases treated with radionuclide palliative therapy (RPT) [48] and in breast cancer cell lines treated with the miR-520/373 family [24], or where the ABL (Abelson murine leukemia) family of non-receptor tyrosine kinases, ABL1 (also known as c-Abl) and ABL2 (also known as Arg), was depleted [36].